A5079980990- Antiplatelet Therapy and Cardiovascular Diseases
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Erythrocyte Function and Pathophysiology
- Venous Thromboembolism Diagnosis and Management
- Acute Ischemic Stroke Management
- Cardiac Arrest and Resuscitation
- Blood Coagulation and Thrombosis Mechanisms
- Atrial Fibrillation Management and Outcomes
- Sepsis Diagnosis and Treatment
- Acute Myocardial Infarction Research
- Diabetes Treatment and Management
- Hemophilia Treatment and Research
- Cerebrovascular and Carotid Artery Diseases
- Inflammatory mediators and NSAID effects
- Cardiac electrophysiology and arrhythmias
- Lipoproteins and Cardiovascular Health
- Meta-analysis and systematic reviews
- Food Allergy and Anaphylaxis Research
- COVID-19 Clinical Research Studies
- Clostridium difficile and Clostridium perfringens research
- Inflammatory Biomarkers in Disease Prognosis
- Disaster Response and Management
- Potassium and Related Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Medical University of Vienna
2017-2025
Georg Fischer (Switzerland)
2020
Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as promising therapeutic strategy.
The optimal systolic blood pressure (SBP) target in patients with increased cardiovascular risk remains uncertain. This study evaluated the efficacy and safety of intensive SBP control (<120 mm Hg) compared to standard (<140 risk. We conducted a systematic search PubMed, Embase, Web Science, Cochrane Library for RCTs published from database inception through November 2024 that adults high Efficacy outcomes included all-cause mortality, major adverse events (MACE), death, stroke, myocardial...
Abstract Background Community-acquired pneumonia (CAP) is associated with high morbidity and mortality. In the present study, we aimed to assess effect of corticosteroids on all-cause mortality in patients hospitalized CAP. Methods For this meta-analysis meta-regression, conducted a systematic search trials that evaluated corticosteroid therapy CAP through March 2023. We included randomized, controlled trials, comparing adjunctive standard care alone for treatment reporting excluded...
Background: Sodium–glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of glucose-lowering drugs that have become increasingly relevant for the treatment and prevention heart failure (HF). Therefore, we aimed to investigate various SGLT2 in patients with established HF at baseline focused on different types HF. Methods: An extensive search PubMed Web Science until January 2021 was done. Two reviewers, independently duplicate, applied selection criteria. This meta-analysis...
Abstract The effect of conventional anti-platelet agents is limited in secondary stroke prevention, and their effects are blunted under high shear stress the presence increased levels circulating von Willebrand factor (VWF). VWF critically involved thrombus formation at sites stenotic extracranial/intracranial arteries. A third generation anti-VWF aptamer (BT200) has been generated which could be useful for prevention. To characterize BT200 blood patients with large artery atherosclerosis...
Von Willebrand factor (VWF) and VIII (FVIII) circulate in a noncovalent complex blood promote primary hemostasis clotting, respectively. A new VWF A1-domain binding aptamer, BT200, demonstrated good subcutaneous bioavailability long half-life non-human primates. This first-in-human, randomized, placebo-controlled, doubleblind trial tested the hypothesis that BT200 is well tolerated has favorable pharmacokinetic pharmacodynamic effects 112 volunteers. Participants received one of following:...
BackgroundToxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by Staphylococcus aureus that causes the life-threatening toxic syndrome. The development of safe and immunogenic vaccine against TSST-1 remains an unmet medical need. We investigated safety, tolerability immunogenicity recombinant variant (rTSST-1v) after 1–3 injections in healthy volunteers.MethodsIn this randomised, double-blind, adjuvant-controlled, parallel-group, phase 2 trial, adults aged 18–64 were randomly...
Microcirculatory alterations are predictive of poor outcomes in patients with shock and after cardiac arrest animal models. However, microcirculatory during human have not yet been studied. We prospectively included adult receiving resuscitation witnessed out-of-hospital arrest. Exclusion criteria were hypovolemia, hypo- or hyperthermia (< 34.0 °C, > 37.5 °C), peripheral arterial disease, Raynaud's logistical issues (e.g., shortage space). Capillary refill time was measured on the finger...
Because of the initially urgent need for treatments COVID-19-associated acute respiratory distress syndrome (ARDS), efficacy and tolerability inhaled solnatide, a direct activator epithelial sodium channel (ENaC) under clinical investigation treatment ARDS, were assessed in pilot trial. This randomized controlled double-blind trial was performed at two study centers Vienna, Austria. Adult mechanically ventilated patients with moderate to severe ARDS (Berlin Definition) caused by COVID-19 1:1...
Abstract The protease-activated receptor-1 (PAR-1) is critically involved in the co-activation of coagulation and inflammatory responses. Vorapaxar a reversible, orally active, low molecular weight, competitive antagonist PAR-1.We investigated effects PAR-1 inhibition by vorapaxar on response, activation coagulation, fibrinolysis endothelium during experimental endotoxemia. In this randomized, double blind, crossover trial, 16 healthy volunteers received bolus infusion 2 ng/kg...
Cold agglutinin disease (CAD) causes predominantly extravascular hemolysis and anemia via complement activation. Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway factor C1s. We aimed to evaluate the safety efficacy of long-term maintenance treatment with sutimlimab in patients CAD. Seven CAD treated as part phase 1B study were transitioned named patient program. After loading dose, received biweekly (once every 2 weeks) infusions at various doses. When...
Abstract Type 2B von Willebrand disease (VWD) is characterized by an increased binding affinity of factor (VWF) to platelet glycoprotein Ib. This can lead clearance high-molecular-weight (HMW) multimers and thrombocytopenia with a resulting moderate-severe bleeding phenotype. Rondoraptivon pegol (BT200) pegylated aptamer the A1 domain VWF novel mechanism action: it enhances VWF/factor VIII (FVIII) levels decreasing their clearance. To study potential benefit rondoraptivon in patients type...
We report the case of a 19-year-old male who complained myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, urinary dipstick tested positive for blood, indicative acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out further diagnostics...
Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF/FVIII healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharmacodynamics hemophilia A. Nineteen adult patients (ages 20-62 years, 4 women) A (8 mild, 2 moderate, 9 severe) received subcutaneous injections pegol. After an initial fixed dose 3 mg on days 0 4, weekly...
Abstract Background Bacterial co-infections are believed to be less frequent in patients with Covid-19 than influenza, but frequencies varied between studies. Methods This single-center retrospective, propensity score-matched analysis included adult or influenza admitted normal-care wards 02/2014 and 12/2021. cases were score matched at a 2:1 ratio. Community-acquired hospital-acquired bacterial defined as positive blood respiratory cultures ≤ 48 h > after hospital admission,...
Abstract Von Willebrand factor (VWF) plays a major role in arterial thrombosis. Antiplatelet drugs induce only moderate relative risk reduction after atherothrombosis, and their inhibitory effects are compromised under high shear rates when VWF levels increased. Therefore, we investigated the ex vivo of third-generation anti-VWF aptamer (BT200) before/after stimulated release. We studied concentration-effect curves BT200 had on activity, platelet plug formation (PFA), ristocetin-induced...